^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ezetimibe/simvastatin

    i
    Other names: MK-0653A
    Company:
    Generic mfg.
    Drug class:
    HMG-CoA reductase inhibitor, Cholesterol absorption inhibitor
    Related drugs:
    2ms
    Effects of Ezetimibe, Statins, and Their Combination on Nuclear Factor Erythroid 2‑Related Factor 2/Heme Oxygenase-1/Kelch-like ECH-Associated Protein‑1 Signaling and Inflammatory Markers in Indomethacin-Induced Gastric Ulcer in Rats. (PubMed, ACS Pharmacol Transl Sci)
    Rats were assigned into six groups (n = 8, each): (I) normal (control), (II) gastric ulcer induced with a single oral dose of indomethacin (30 mg/kg body weight), (III) rats received oral simvastatin (40 mg/kg/day) for 14 days, (IV) rats received oral ezetimibe (10 mg/kg/day) for 14 days, (V) the combination group received both oral simvastatin and ezetimibe, and (VI) standard group received oral famotidine (20 mg/kg). Simvastatin plus ezetimibe exerted synergistic gastroprotective effects in rats, associated with Nrf2/HO-1 activation and suppression of Keap1, oxidative stress, and pro-inflammatory cytokines. This combination may represent a novel therapeutic approach for preventing NSAID-induced GUs, meriting further mechanistic and translational studies.
    Preclinical • Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • CRP (C-reactive protein)
    |
    KEAP1 mutation
    |
    simvastatin • ezetimibe/simvastatin
    over1year
    Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer (clinicaltrials.gov)
    P2, N=140, Recruiting, Cedars-Sinai Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8)
    |
    sirolimus • ezetimibe/simvastatin
    over1year
    Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer (clinicaltrials.gov)
    P2, N=140, Not yet recruiting, Cedars-Sinai Medical Center
    New P2 trial
    |
    CD8 (cluster of differentiation 8)
    |
    sirolimus • ezetimibe/simvastatin
    almost2years
    To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects (clinicaltrials.gov)
    P=N/A, N=20, Completed, University at Buffalo | Unknown status --> Completed | Phase classification: P3 --> PN/A
    Trial completion • Phase classification
    |
    CD68 (CD68 Molecule)
    |
    simvastatin • ezetimibe/simvastatin